Dialyzer Reaction (Type A / Anaphylactic)

1. Executive Overview: Understanding Type A Dialyzer Reactions

A Type A dialyzer reaction, clinically classified under ICD-10 code T80.52XA, represents a severe, life-threatening anaphylactic response occurring during or shortly after the initiation of hemodialysis. Unlike the more common, milder Type B reactions (which are typically associated with complement activation and chest/back pain), Type A reactions are characterized by immediate IgE-mediated hypersensitivity.

In the context of nephrology, recognizing the distinction between Type A and Type B is paramount. While Type B reactions are often managed by continuing dialysis with symptomatic relief, Type A reactions mandate immediate termination of the procedure, disconnection of the extracorporeal circuit, and aggressive emergency resuscitation. For patients with advanced Chronic Kidney Disease (CKD) or End-Stage Renal Disease (ESRD) managed via dialysis, these reactions present a catastrophic acute event that requires a multidisciplinary approach to prevent long-term systemic sequelae.

2. Pathophysiology, Etiology, and Risk Factors

The Mechanism of Hypersensitivity

The pathophysiology of a Type A reaction is driven by a rapid immunological cascade. The most common trigger is the exposure of the patient’s blood to the dialyzer membrane, particularly membranes containing ethylene oxide (EtO), which is used as a sterilizing agent.

• IgE-Mediated Response: The patient develops specific IgE antibodies against EtO. Upon exposure, these antibodies trigger mast cell degranulation, releasing histamine, leukotrienes, and prostaglandins, leading to systemic vasodilation, bronchospasm, and hypotension.
• Bradykinin Pathway: In patients taking ACE inhibitors (ACEi), the inhibition of kininase II prevents the breakdown of bradykinin. During dialysis, the contact of blood with the artificial membrane can stimulate the kallikrein-kinin system, resulting in excessive bradykinin accumulation and profound, refractory hypotension.

Risk Factors and Clinical Associations

The clinical profile of the patient is a critical determinant. Patients with CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder) often exhibit complex systemic inflammatory states that may lower the threshold for anaphylaxis.

3. Signs, Symptoms, and Clinical Presentation

Type A reactions occur within the first 5 to 30 minutes of dialysis initiation. The presentation is rapid and systemic.

• Respiratory: Dyspnea, laryngeal edema, wheezing, and cyanosis.
• Cardiovascular: Acute, severe hypotension, tachycardia, and cardiac arrest.
• Dermatological: Urticaria, pruritus, and angioedema.
• Gastrointestinal: Abdominal cramping, nausea, and vomiting.

It is essential for the clinical team to distinguish this from uremic pericarditis or acute myocardial infarction, both of which can present with chest pain and hemodynamic instability in the ESRD population.

4. Diagnostic Evaluation and Workup

Diagnostic evaluation is largely clinical, given the emergent nature of the event. However, post-stabilization workup is necessary to identify the trigger and prevent recurrence.

Laboratory and Renal Assessment

• eGFR and Creatinine Trends: While ESRD patients are anuric or oliguric, monitoring baseline creatinine and urea clearance is vital to assess if the dialysis session was sufficient before the interruption.
• Renal Biopsy Indications: If the patient presents with new-onset nephrotic-range proteinuria or hematuria unrelated to the reaction, a renal biopsy may be indicated to rule out underlying glomerulonephritis (e.g., membranous nephropathy or focal segmental glomerulosclerosis) that may complicate the patient’s overall renal prognosis.
• IgE Assays: Testing for specific anti-EtO IgE antibodies may be performed in specialized centers.

KDIGO Staging and Long-Term Management

Following an acute Type A reaction, the patient’s KDIGO Stage 5D status must be reassessed. The focus shifts from acute stabilization to the optimization of long-term renal replacement therapy (RRT). Management of CKD-MBD is crucial; ensuring calcium-phosphate homeostasis prevents the compounding stress of secondary hyperparathyroidism on the cardiovascular system.

5. Therapeutic Interventions

Immediate Emergency Management

1. Stop Dialysis: Immediately clamp the blood lines. Do NOT return the blood to the patient, as it may contain the offending agent.
2. Pharmacotherapy:
   • Epinephrine: 0.3–0.5 mg (1:1000) intramuscularly is the first-line treatment.
   • Antihistamines: Diphenhydramine (H1 blocker) and Ranitidine or Famotidine (H2 blocker).
   • Corticosteroids: Methylprednisolone to prevent late-phase reactions.
   • Bronchodilators: Albuterol nebulization for bronchospasm.
3. Hemodynamic Support: Aggressive fluid resuscitation with isotonic crystalloids.

Long-Term Prevention

• Membrane Switch: Transition the patient to a dialyzer sterilized with steam or gamma radiation rather than EtO.
• Circuit Priming: Ensure thorough flushing of the extracorporeal circuit with large volumes of saline (at least 1–2 liters) prior to initiation to remove residual sterilants.
• Medication Review: Discontinue ACE inhibitors if the reaction is suspected to be bradykinin-mediated.

6. Frequently Asked Questions (FAQ)

1. What is the primary difference between a Type A and Type B reaction?
Type A is an IgE-mediated anaphylactic reaction requiring immediate termination. Type B is a milder, complement-mediated reaction often characterized by chest pain and back pain that may resolve during the session.

2. Can an ACE inhibitor cause a Type A reaction?
Yes. ACE inhibitors prevent the breakdown of bradykinin, which can accumulate during hemodialysis and cause severe hypotension and anaphylactoid symptoms.

3. Is a renal biopsy required after a Type A reaction?
Not for the reaction itself. However, if the patient has unexplained renal pathology or worsening glomerular filtration, a biopsy may be indicated to evaluate for underlying nephritic or nephrotic disease.

4. How does CKD-MBD impact my risk?
CKD-MBD reflects the systemic burden of renal failure. Patients with advanced mineral bone disease often have increased vascular calcification, making them more susceptible to the cardiovascular stress caused by an anaphylactic event.

5. How are dialyzers sterilized to prevent these reactions?
Many centers now use steam or gamma-ray sterilization, which eliminates the use of ethylene oxide, the most common culprit in Type A reactions.

6. What should I do if I feel symptoms starting during dialysis?
Alert the nursing staff immediately. Do not wait to see if the symptoms pass; early intervention with epinephrine is critical for survival.

7. Can I continue the same dialysis session after the reaction?
No. Once a Type A reaction is suspected, the circuit must be discarded and the blood must not be returned to the patient.

8. Are these reactions common?
Type A reactions are rare, occurring in less than 0.5% of dialysis sessions, but they are highly dangerous.

9. How does this affect my KDIGO staging?
The reaction does not change your KDIGO stage (which is based on GFR), but it necessitates a review of your RRT modality and may lead to a switch in dialysis equipment or medication regimens.

10. Is this reaction hereditary?
No, Type A reactions are an acquired hypersensitivity to materials used in the dialysis process, not an inherited genetic disorder.

Related Clinical Integration

In the event of a Type A dialyzer reaction, immediate clinical intervention is mandatory to stabilize the patient, beginning with the Discontinuation of Dialysis and the removal of the Dialysis Filter/Dialyzer to prevent further exposure to the inciting agent. Management requires rapid assessment using a Sphygmomanometer, Pulse Oximeter, and Cardiac Monitor to monitor hemodynamic stability, while securing access via an Intravenous Catheter for Intravenous fluid resuscitation using Saline. Pharmacological stabilization involves the administration of Epinephrine / إبينفرين 1mg/10ml, Hydrocortisone / هيدروكورتيزون 100mg/60mL, Depo-Medrol / ديبو-ميدرول 80 mg, and Diphenhydramine / ديفينهيدرامين Standard or other